EUCTR2015-002106-36-RO进行中（未招募）1 期
The effects of JNJ-39393406 on psychometric performance and residual depressive symptoms in 80 patients with unipolar or bipolar depression: a phase II exploratory add-on double blind placebo controlled 2 week trial
Clinirx Tangent Research0 个研究点目标入组 80 人开始时间: 2015年10月26日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Meet DSM V criteria for history of MDD or BPD by MINI.
- •2.Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers.
- •3.Able to provide informed consent. All participant patients must have signed an informed consent document indicating they understand the purpose of the study and the procedures required for the study and are willing to participate by complying with the study procedures and restrictions.
- •4.Have a MADRS = 10 and = 34 and an YMRS < 7.
- •5.In the opinion of the investigator, basic education and severity of symptoms (psychotic, negative, manic, agitation, depression) do not prevent the patient from attending to the cognitive tasks.
- •6.In the opinion of the investigator the patient can be safely treated with no more than 2 psychotropic medications as background therapy (SOS for agitation and sleeping medication are allowed in addition to the 2 psychotropics).
- •7.The background psychotropic(s) that will be continued through-out the 2 week trial must have been started at least 2 weeks prior to the baseline day at doses allowed by the local regulations and no changes in dose have been made during this pre-baseline 2 week period.
- •8. Inpatients or out-patients at the discretion of the investigator (If outpatients the Readiness for Discharge Scale has to be administered at baseline and at each visit.)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Women of child bearing potential who do not practice contraception.
- •2.Psychosis, florid manic or major depressive episode during the 4 weeks preceding baseline day or current psychosis.
- •3.Patients on more than 2 psychotropic (hypnotics for sleep and occasional SOS for agitation do not count).
- •4.Smokes more than 40 cigarettes per day.
- •5.Unstable medical disease (malignancy, poorly controlled diabetes, or cardiomyopathy, serious pulmonary disease, kidney disease, impaired liver functioning. Particular attention should be given to exclude patients with ischemic heart disease).
- •6.Has a clinically significant abnormal 12-lead electrocardiogram (ECG) at Screening Visit 1 as determined by the Investigator.
- •7.At significant risk of committing suicide, or in the opinion of the Investigator, currently is at imminent risk of suicide or harming others.
- •8.Patients with a current DSM-IV substance or alcohol dependence.
- •9.Concurrent delirium, mental retardation, drug-induced psychosis, or history of stroke, brain degenerative disorders and brain trauma.
研究者
相似试验
已完成
2 期
The Effects of JNJ-39393406 on Psychometric Performance and Residual DepressiveDepressionNCT02677207Tangent Data80
已完成
1 期
A Study to Investigate How JNJ-38518168 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis ParticipantsRheumatoid ArthritisNCT01450982Johnson & Johnson Pharmaceutical Research & Development, L.L.C.20
已完成
1 期
A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and PlasmaHealthyNCT02933762Janssen Research & Development, LLC25
进行中（未招募）
2 期
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseasePreclinical Alzheimer's DiseaseAlzheimer DiseaseNCT06544616Janssen Pharmaceutica N.V., Belgium55
已完成
1 期
Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer DementiaAlzheimer's DiseaseNCT02360657Janssen Pharmaceutical K.K.18